CELLMED (셀메드)

Cellmed Orthocellular Medicine and Pharmaceutical Association (셀메드 세포교정의약학회)
권호 표지
DOI QR코드

DOI QR Code

The spiritual sense, prayer and traditional American Indian healing

  • Adams, James David Jr. (Department of Pharmacology and Pharmaceutical Sciences, School of Pharmacy, University of Southern California) ;
  • Garcia, Cecilia (Department of Pharmacology and Pharmaceutical Sciences, School of Pharmacy, University of Southern California)
  • Received : 2011.06.15
  • Accepted : 2012.02.29
  • Published : 2012.02.29
Download PDF
⟨ Previous Next ⟩

Abstract

A spiritual sense may be present in the human brain. Demonstration of the spiritual sense depends on measuring the behavioral effects of spiritual experiences. These experiences can be induced by prayer, specific chemicals and other stimuli that are known to interact with pyramidal neurons of layer 5 in the cerebral cortex. This work examines the hypothesis that pyramidal neurons are the seat of the spiritual sense. Healers use the spiritual sense to comfort and heal their patients, especially with prayer. Many doctors do not encourage prayer and could learn from healers to use the spiritual sense. Patients should be educated to use prayer in order to get the comfort they need for healing.

Keywords

References

  1. Adams JD, Garcia C. Palliative care among Chumash people. Evid Based Complement Alternat Med. 2005;2(2):143-147. https://doi.org/10.1093/ecam/neh090
  2. Adams JD Jr, Garcia C. Spirit, mind and body in Chumash healing. Evid Based Complement Alternat Med. 2005;2(4):459-463. https://doi.org/10.1093/ecam/neh130
  3. Alkondon M, Albuquerque EX. The nicotinic acetylcholine receptor subtypes and their function in the hippocampus and cerebral cortex. Prog Brain Res. 2004;145:109-120. https://doi.org/10.1016/S0079-6123(03)45007-3
  4. al-Krenawi A, Graham JR, Maoz B. The healing significance of the Negev's Bedouin Dervish. Soc Sci Med. 1996;43(1):13-21. https://doi.org/10.1016/0277-9536(95)00316-9
  5. Appel JB, Callahan PM. Involvement of 5-HT receptor subtypes in the discriminative stimulus properties of mescaline. Eur J Pharmacol. 1989;159(1):41-46. https://doi.org/10.1016/0014-2999(89)90041-1
  6. Astin JA, Harkness E, Ernst E. The efficacy of "distant healing": a systematic review of randomized trials. Ann Intern Med. 2000;132(11):903-910. https://doi.org/10.7326/0003-4819-132-11-200006060-00009
  7. Buhner SH. Sacred Plant Medicine Explorations in the Practice of Indigenous Herbalism. (USA: Raven Press), 1996.
  8. Kotler A. In engaged Buddhist reader ten years of engaged Buddhist publishing. (CA: Parallax Press), pp. 3-6, 1996.
  9. Dringenberg HC, Sparling JS, Frazer J, Murdoch J. Generalized cortex activation by the auditory midbrain: mediation by acetylcholine and subcortical relays. Exp Brain Res. 2006;174(1):114-123. https://doi.org/10.1007/s00221-006-0427-5
  10. Dringenberg HC, Yahia N, Cirasuolo J, McKee D, Kuo MC. Neocortical activation by electrical and chemical stimulation of the rat inferior colliculus: intra-collicular mapping and neuropharmacological characterization. Exp Brain Res. 2004;154(4):461-469. https://doi.org/10.1007/s00221-003-1675-2
  11. Faber ES, Sah P. Opioids inhibit lateral amygdala pyramidal neurons by enhancing a dendritic potassium current. J Neurosci. 2004;24(12):3031-3039. https://doi.org/10.1523/JNEUROSCI.4496-03.2004
  12. El-Seedi HR, De Smet PA, Beck O, Possnert G, Bruhn JG. Prehistoric peyote use: alkaloid analysis and radiocarbon dating of archaeological specimens of Lophophora from Texas. J Ethnopharmacol. 2005;101(1-3):238-242. https://doi.org/10.1016/j.jep.2005.04.022
  13. Faber ES, Sah P. Opioids inhibit lateral amygdala pyramidal neurons by enhancing a dendritic potassium current. J Neurosci. 2004;24(12):3031-3039. https://doi.org/10.1523/JNEUROSCI.4496-03.2004
  14. Griffiths RR, Richards WA, McCann U, Jesse R. Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance. Psychopharmacology. 2006;187(3):268-283. https://doi.org/10.1007/s00213-006-0457-5
  15. Hofmann A. Teonanacatl and Ololiuqui: Two ancient magic drugs of Mexico. Bull Narcotics. 1971;23:3-14.
  16. Kavasch EB, Baar K. American Indian Healing Arts Herbs, Rituals, and Remedies for Every Season of Life. (USA: Bantam), 1999.
  17. Li Y, Husbands SM, Mahon MF, Traynor JR, Rowan MG. Isolation and chemical modification of clerodane diterpenoids from Salvia species as potential agonists at the kappa opioid receptor. Chem Biodivers. 2007;4(7):1586-1593. https://doi.org/10.1002/cbdv.200790138
  18. Marek GJ, Aghajanian GK. 5-Hydroxytryptamine induced excitatory postsynaptic currents in neocortical layer V pyramidal cells: suppression by u-opiate receptor activation. Neuroscience. 1998;86(2):485-497. https://doi.org/10.1016/S0306-4522(98)00043-8
  19. McNamara P, Durso R, Brown A, Harris E. The chemistry of religiosity: evidence from patients with Parkinson's disease. In: Where God and Science Meet. How Brain and Evolutionary Studies Alter our Understanding of Religion. McNamara P ed. (Westport: Praeger Publishers), pp. 1-14, 2006.
  20. Monte AP, Waldman SR, Marona-Lewicka D, Wainscott DB, Nelson DL, Sanders-Bush E, Nichols DE. Dihydrobenzofuran analogues of hallucinogens. 4. Mescaline derivatives. J Med Chem. 1997;40(19):2997-3008. https://doi.org/10.1021/jm970219x
  21. Newberg A, Waldman MR. How God changes your brain breakthrough findings from a leading neuroscientist. (USA: Ballantine Books), 2010.
  22. Nichols DE, Chemel BR. The neuropharmacology of religious experience: hallucinogens and the experience of the divine. In Where God and Science Meet How Brain and Evolutionary Studies Alter our Understanding of Religion. Volume 3. The Psychology of Religious Experience, McNamara P ed. (Westport: Praeger Publishers), pp. 1-33, 2006.
  23. Nichols DE. Hallucinogens. Pharmacol Ther. 2004;101(2):131-181. https://doi.org/10.1016/j.pharmthera.2003.11.002
  24. Nolte KB, Zumwalt RE. Fatal peyote ingestion associated with Mallory-Weiss lacerations. Wester J Med. 1999;170(6):328.
  25. Oken BS. Placebo effects: clinical aspects and neurobiology. Brain. 2008;131(Pt 11):2812-2823. https://doi.org/10.1093/brain/awn116
  26. Piek T. Neurotoxins from venoms of the Hymenoptera-twenty five years of research in Amsterdam. Comp Biochem Physiol C. 1990;96(2):223-233. https://doi.org/10.1016/0742-8413(90)90001-P
  27. Polsky A, Mel BW, Schiller J. Computational subunits in thin dendrites of pyramidal cells. Nat Neurosci. 2004;7(6):621-627. https://doi.org/10.1038/nn1253
  28. Radosevich PM, Nash JA, Lacy DB, O'Donovan C, Williams PE, Abumrad NN. Effects of low and high intensity exercise on plasma and cerebrospinal fluid levels of ir-beta-endorphin, ACTH, cortisol, norepinephrine and glucose in the conscious dog. Brain Res. 1989;498(1):89-98. https://doi.org/10.1016/0006-8993(89)90402-2
  29. Riba J, Rodríguez-Fornells A, Barbanoj MJ. Effects of ayahuasca on sensory and sensorimotor gating in humans as measured by P50 suppression and prepulse inhibition of the startle reflex, respectively. Psychopharmacology. 2002;165(1):18-28. https://doi.org/10.1007/s00213-002-1237-5
  30. Roberts TB. Chemical input, religious output - entheogens: apharmatheology sampler. In Where God and Science Meet How Brain and Evolutionary Studies Alter our Understanding of Religion. Volume 3. The Psychology of Religious Experience, McNamara P ed. (Westport: Praeger Publishers), pp. 235-67, 2006.
  31. Rutledge T, Reis SE, Olson M, Owens J, Kelsey SF, Pepine CJ, Mankad S, Rogers WJ, Bairey Merz CN, Sopko G, Cornell E, Sharaf B, Matthews KA. Social networks are associated with lower mortality rates among women with suspected coronary artery disease: the National Heart, Lung and Blood Institute sponsored women's ischemia syndrome evaluation study. Psychosom Med. 2004;66(6):882-888. https://doi.org/10.1097/01.psy.0000145819.94041.52
  32. Salak K. The Amazon's Shaman therapy. Nat Geo Adventure. March 2006;1-4.
  33. Seeman P, Guan HC, Hirbec H. Dopamine D2High receptors stimulated by phencyclidines, lysergic acid diethylamide, salvinorin A, and modafinil. Synapse. 2009;63(8):698-704. https://doi.org/10.1002/syn.20647
  34. Shulgin A, Shulgin A. Pihkal a Chemical Love Story. (CA: Transform Press), 1991.
  35. Sjostrom PJ, Häusser M. A cooperative switch determines the sign of synaptic plasticity in distal dendrites of neocortical pyramidal neurons. Neuron. 2006;51(2):227-238. https://doi.org/10.1016/j.neuron.2006.06.017
  36. Smith DE, Cromy R, Downing J, Sutton L. Symposium: Psychedelic drugs and religion. J Psychedelic Drugs. 1967;1(2):1-19. https://doi.org/10.1080/02791072.1967.10524336
  37. Tayebati SK, Di Tullio MA, Amenta F. Muscarinic cholinergic receptor subtypes in cerebral cortex of Fisher 344 rats: a light microscopic autoradiography study of age related changes. Mech Ageing Deve. 2006;127(2):115-122. https://doi.org/10.1016/j.mad.2005.09.024
  38. Vollenweider FX, Vontobel P, Hell D, Leenders KL. 5-HT modulation of dopamine release in basal ganglia in psilocybin induced psychosis in man a PET study with [11C]raclopride. Neuropsychopharmacology. 1999;20(5):424-433. https://doi.org/10.1016/S0893-133X(98)00108-0
  39. Walsh SL, Strain EC, Abreu ME, Bigelow GE. Enadoline, a selective kappa opioid agonist: comparison with butorphanol and hydromorphone in humans. Psychopharmacology. 2001;157(2):151-162. https://doi.org/10.1007/s002130100788
  40. Wang Z, Kai L, Day M, Ronesi J, Yin HH, Ding J, Tkatch T, Lovinger DM, Surmeier DJ. Dopaminergic control of corticostriatal long term synaptic depression in medium spiny neurons is mediated by cholinergic interneurons. Neuron. 2006;50(3):443-452. https://doi.org/10.1016/j.neuron.2006.04.010
  41. Wasson RG. The Wondrous Mushroom: Mycolatry in Mesoamerica. (USA: McGraw-Hill), 1980.
  42. Zhang Y, Hamilton SE, Nathanson NM, Yan J. Decreased input specific plasticity of the auditory cortex in mice lacking M1 muscarinic acetylcholine receptors. Cerebral Cortex. 2006;16(9):1258-1265. https://doi.org/10.1093/cercor/bhj067

Cited by

  1. Does the World Need Plant Medicines? vol.5, pp.2, 2018, https://doi.org/10.3390/medicines5020039